Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data
Background: Combination therapy using an immune checkpoint inhibitor (ICI) and a tyrosine kinase inhibitor (TKI) is the standard first-line treatment for metastatic renal cell carcinoma (RCC). Oral TKIs enhance patient autonomy but require strict adherence and persistence. Methods: We analyzed adult...
Saved in:
| Main Authors: | Zhaohui Liao Arter, David J Benjamin, Yen Cao, Jorge Farias, Ranjit Kumar Thirumaran, Michael Forsyth, Nataliya Mar, Arash Rezazadeh Kalebasty |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/11795549251341877 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01) -
TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01) -
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
by: Omer Faruk Kuzu, et al.
Published: (2025-07-01) -
Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancers
by: Tai Van Nguyen, et al.
Published: (2025-04-01) -
Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
by: Marilda Mormando, et al.
Published: (2024-12-01)